Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.

Iwasaki S, Kosugi Y, Zhu AZX, Nakagawa S, Sano N, Funami M, Kosaka M, Furuta A, Hirabayashi H, Amano N.

Xenobiotica. 2018 Dec 5:1-9. doi: 10.1080/00498254.2018.1547461. [Epub ahead of print]

PMID:
30516093
2.

Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology.

Zhu AZ.

Future Sci OA. 2018 Apr 23;4(5):FSO306. doi: 10.4155/fsoa-2017-0152. eCollection 2018 Jun. Review.

3.

Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Tanner JA, Zhu AZ, Claw KG, Prasad B, Korchina V, Hu J, Doddapaneni H, Muzny DM, Schuetz EG, Lerman C, Thummel KE, Scherer SE, Tyndale RF.

Pharmacogenet Genomics. 2018 Jan;28(1):7-16. doi: 10.1097/FPC.0000000000000317.

4.

Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.

Chenoweth MJ, Ware JJ, Zhu AZX, Cole CB, Cox LS, Nollen N, Ahluwalia JS, Benowitz NL, Schnoll RA, Hawk LW Jr, Cinciripini PM, George TP, Lerman C, Knight J, Tyndale RF; PGRN-PNAT Research Group.

Addiction. 2018 Mar;113(3):509-523. doi: 10.1111/add.14032. Epub 2017 Nov 2.

5.

Inhibition of Adipogenesis Is Involved in the Protective Effects of 1,25-Dihydroxy Vitamin D3 on the Radiation-Injured Bone Marrow Microenvironment in Mice.

Zhou Z, Chen XY, Zhu AZ, Liu CC, Zhu JC, Liu GX.

J Nutr Sci Vitaminol (Tokyo). 2017;63(3):161-166. doi: 10.3177/jnsv.63.161.

6.

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.

Wolenski FS, Zhu AZX, Johnson M, Yu S, Moriya Y, Ebihara T, Csizmadia V, Grieves J, Paton M, Liao M, Gemski C, Pan L, Vakilynejad M, Dragan YP, Chowdhury SK, Kirby PJ.

Toxicol Sci. 2017 May 1;157(1):50-61. doi: 10.1093/toxsci/kfx018.

7.

The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.

Moerke MJ, Zhu AZ, Tyndale RF, Javors MA, McMahon LR.

Neuropharmacology. 2017 Apr;116:9-17. doi: 10.1016/j.neuropharm.2016.12.003. Epub 2016 Dec 8.

9.

COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.

Lu R, Hu X, Zhou J, Sun J, Zhu AZ, Xu X, Zheng H, Gao X, Wang X, Jin H, Zhu P, Guo L.

Nat Commun. 2016 Jul 4;7:12044. doi: 10.1038/ncomms12044.

10.

Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2.

Ware JJ, Chen X, Vink J, Loukola A, Minica C, Pool R, Milaneschi Y, Mangino M, Menni C, Chen J, Peterson RE, Auro K, Lyytikäinen LP, Wedenoja J, Stiby AI, Hemani G, Willemsen G, Hottenga JJ, Korhonen T, Heliövaara M, Perola M, Rose RJ, Paternoster L, Timpson N, Wassenaar CA, Zhu AZ, Davey Smith G, Raitakari OT, Lehtimäki T, Kähönen M, Koskinen S, Spector T, Penninx BW, Salomaa V, Boomsma DI, Tyndale RF, Kaprio J, Munafò MR.

Sci Rep. 2016 Feb 1;6:20092. doi: 10.1038/srep20092.

11.

Stress Relaxation for Granular Materials near Jamming under Cyclic Compression.

Farhadi S, Zhu AZ, Behringer RP.

Phys Rev Lett. 2015 Oct 30;115(18):188001. doi: 10.1103/PhysRevLett.115.188001. Epub 2015 Oct 29.

PMID:
26565498
12.

Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice.

Alsharari SD, King JR, Nordman JC, Muldoon PP, Jackson A, Zhu AZ, Tyndale RF, Kabbani N, Damaj MI.

PLoS One. 2015 Sep 10;10(9):e0137070. doi: 10.1371/journal.pone.0137070. eCollection 2015.

13.

Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption.

Bergen AW, Michel M, Nishita D, Krasnow R, Javitz HS, Conneely KN, Lessov-Schlaggar CN, Hops H, Zhu AZ, Baurley JW, McClure JB, Hall SM, Baker TB, Conti DV, Benowitz NL, Lerman C, Tyndale RF, Swan GE; Transdisciplinary Research in Cancer of the Lung Research Team.

PLoS One. 2015 Jul 1;10(7):e0126113. doi: 10.1371/journal.pone.0126113. eCollection 2015.

14.

Inhibition of adipogenic differentiation of bone marrow mesenchymal stem cells by erythropoietin via activating ERK and P38 MAPK.

Liu GX, Zhu JC, Chen XY, Zhu AZ, Liu CC, Lai Q, Chen ST.

Genet Mol Res. 2015 Jun 26;14(2):6968-77. doi: 10.4238/2015.June.26.5.

15.

Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking.

Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, Swan GE, Benowitz NL, Heitjan DF, Lerman C; PGRN-PNAT Research Group.

PLoS One. 2015 May 26;10(5):e0128109. doi: 10.1371/journal.pone.0128109. eCollection 2015.

16.

Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.

Zhu AZ, Cox LS, Ahluwalia JS, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF.

Pharmacogenet Genomics. 2015 May;25(5):263-9. doi: 10.1097/FPC.0000000000000135.

17.

Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes.

Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF.

Drug Metab Dispos. 2014 Nov;42(11):1971-7. doi: 10.1124/dmd.114.060285. Epub 2014 Sep 3.

18.

Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.

Bagdas D, Muldoon PP, Zhu AZ, Tyndale RF, Damaj MI.

Neuropharmacology. 2014 Oct;85:67-72. doi: 10.1016/j.neuropharm.2014.05.006. Epub 2014 May 21.

19.

Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers.

Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, Tyndale RF.

Clin Pharmacol Ther. 2014 Aug;96(2):256-65. doi: 10.1038/clpt.2014.88. Epub 2014 Apr 14.

20.

Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption.

Chenoweth MJ, Zhu AZ, Sanderson Cox L, Ahluwalia JS, Benowitz NL, Tyndale RF.

Pharmacogenet Genomics. 2014 Mar;24(3):172-6. doi: 10.1097/FPC.0000000000000031.

21.

Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.

Piliguian M, Zhu AZ, Zhou Q, Benowitz NL, Ahluwalia JS, Sanderson Cox L, Tyndale RF.

Pharmacogenet Genomics. 2014 Feb;24(2):118-28. doi: 10.1097/FPC.0000000000000026.

22.

Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.

Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF.

PLoS One. 2013 Aug 2;8(8):e70938. doi: 10.1371/journal.pone.0070938. Print 2013.

23.

CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users.

Zhu AZ, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF.

Addiction. 2013 Oct;108(10):1818-28. doi: 10.1111/add.12250. Epub 2013 Jul 5.

24.

The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.

Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):708-18. doi: 10.1158/1055-9965.EPI-12-1234-T. Epub 2013 Jan 31.

25.

Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.

Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd.

Pharmacogenet Genomics. 2013 Mar;23(3):135-41. doi: 10.1097/FPC.0b013e32835d9ab0.

26.

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion.

Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF.

Clin Pharmacol Ther. 2012 Dec;92(6):771-7. doi: 10.1038/clpt.2012.186. Epub 2012 Nov 14.

27.

Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation.

Zhu AZ, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, Stepanov I, Watson CH, Sosnoff CS, Benowitz NL, Tyndale RF.

Carcinogenesis. 2013 Jan;34(1):93-101. doi: 10.1093/carcin/bgs306. Epub 2012 Oct 1.

28.

CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.

Binnington MJ, Zhu AZ, Renner CC, Lanier AP, Hatsukami DK, Benowitz NL, Tyndale RF.

Pharmacogenet Genomics. 2012 Jun;22(6):429-40. doi: 10.1097/FPC.0b013e3283527c1c.

29.

Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.

Gamaleddin I, Wertheim C, Zhu AZ, Coen KM, Vemuri K, Makryannis A, Goldberg SR, Le Foll B.

Addict Biol. 2012 Jan;17(1):47-61. doi: 10.1111/j.1369-1600.2011.00314.x. Epub 2011 Apr 26.

PMID:
21521420
30.

Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment.

Khokhar JY, Ferguson CS, Zhu AZ, Tyndale RF.

Annu Rev Pharmacol Toxicol. 2010;50:39-61. doi: 10.1146/annurev.pharmtox.010909.105826. Review.

PMID:
20055697

Supplemental Content

Support Center